Cargando…

Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and achieves a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor cell survival and proliferation. Using a mouse model of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balachandran, Vinod P., Cavnar, Michael J., Zeng, Shan, Bamboat, Zubin M., Ocuin, Lee M., Obaid, Hebroon, Sorenson, Eric C., Popow, Rachel, Ariyan, Charlotte, Rossi, Ferdinand, Besmer, Peter, Guo, Tianhua, Antonescu, Cristina R., Taguchi, Takahiro, Yuan, Jianda, Wolchok, Jedd D., Allison, James P., DeMatteo, Ronald P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278279/ https://www.ncbi.nlm.nih.gov/pubmed/21873989 http://dx.doi.org/10.1038/nm.2438

Ejemplares similares

KIT oncogene inhibition drives intratumoral macrophage M2 polarization
por: Cavnar, Michael J., et al.
Publicado: (2013)

Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
por: Cavnar, Michael J, et al.
Publicado: (2014)

Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation
por: Sorenson, Eric C., et al.
Publicado: (2017)

SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
por: Italiano, Antoine, et al.
Publicado: (2012)

Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis
por: Plitas, George, et al.
Publicado: (2008)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

The delicate balance of melanoma immunotherapy
por: Gyorki, David E, et al.
Publicado: (2013)

The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor
por: Zhang, Jennifer Q., et al.
Publicado: (2020)

EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases
por: Moore Dalal, Kimberly, et al.
Publicado: (2008)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

Massive malignant solitary fibrous tumor arising from the bladder serosa: a case report
por: Dozier, Jordan, et al.
Publicado: (2015)

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

An adverse tumor-protective effect of IDO1 inhibition
por: Kenski, Juliana C.N., et al.
Publicado: (2023)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease
por: Sucher, Robert, et al.
Publicado: (2010)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1
por: Flick, Hollie E., et al.
Publicado: (2013)

Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants
por: O'Brien, Katie M., et al.
Publicado: (2013)

ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor
por: Zeng, Shan, et al.
Publicado: (2017)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
por: Chi, Ping, et al.
Publicado: (2022)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations
por: O’Brien, Katie M, et al.
Publicado: (2013)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Coupling and Uncoupling of Tumor Immunity and Autoimmunity
por: Bowne, Wilbur B., et al.
Publicado: (1999)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity
por: Zhang, Yujuan, et al.
Publicado: (2020)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation
por: Muller, Alexander J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rd7pi5id35m8j9bi4pcqcig9dp